vs
Apellis Pharmaceuticals, Inc.（APLS）与TOMPKINS FINANCIAL CORP（TMP）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是TOMPKINS FINANCIAL CORP的1.0倍（$199.9M vs $194.8M），TOMPKINS FINANCIAL CORP净利率更高（49.4% vs -29.5%，领先78.9%），TOMPKINS FINANCIAL CORP同比增速更快（152.7% vs -5.9%），TOMPKINS FINANCIAL CORP自由现金流更多（$31.9M vs $-14.3M），过去两年TOMPKINS FINANCIAL CORP的营收复合增速更高（63.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
汤普金斯金融公司是一家小型多元化金融服务企业，总部位于纽约州伊萨卡，是汤普金斯信托银行及其他多家银行、一家保险代理机构和财富管理部门的母公司。
APLS vs TMP — 直观对比
营收规模更大
APLS
是对方的1.0倍
$194.8M
营收增速更快
TMP
高出158.6%
-5.9%
净利率更高
TMP
高出78.9%
-29.5%
自由现金流更多
TMP
多$46.2M
$-14.3M
两年增速更快
TMP
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $194.8M |
| 净利润 | $-59.0M | $96.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 71.7% |
| 净利率 | -29.5% | 49.4% |
| 营收同比 | -5.9% | 152.7% |
| 净利润同比 | -62.2% | 388.9% |
| 每股收益（稀释后） | $-0.40 | $6.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTMP
| Q4 25 | $199.9M | $194.8M | ||
| Q3 25 | $458.6M | $87.4M | ||
| Q2 25 | $178.5M | $82.6M | ||
| Q1 25 | $166.8M | $81.7M | ||
| Q4 24 | $212.5M | $77.1M | ||
| Q3 24 | $196.8M | $76.6M | ||
| Q2 24 | $199.7M | $72.7M | ||
| Q1 24 | $172.3M | $72.8M |
净利润APLSTMP
| Q4 25 | $-59.0M | $96.2M | ||
| Q3 25 | $215.7M | $23.7M | ||
| Q2 25 | $-42.2M | $21.5M | ||
| Q1 25 | $-92.2M | $19.7M | ||
| Q4 24 | $-36.4M | $19.7M | ||
| Q3 24 | $-57.4M | $18.6M | ||
| Q2 24 | $-37.7M | $15.7M | ||
| Q1 24 | $-66.4M | $16.9M |
营业利润率APLSTMP
| Q4 25 | -25.6% | 71.7% | ||
| Q3 25 | 48.7% | 35.6% | ||
| Q2 25 | -18.6% | 34.2% | ||
| Q1 25 | -50.0% | 31.6% | ||
| Q4 24 | -12.3% | 33.4% | ||
| Q3 24 | -24.0% | 32.0% | ||
| Q2 24 | -14.7% | 28.3% | ||
| Q1 24 | -36.0% | 30.4% |
净利率APLSTMP
| Q4 25 | -29.5% | 49.4% | ||
| Q3 25 | 47.0% | 27.1% | ||
| Q2 25 | -23.6% | 26.0% | ||
| Q1 25 | -55.3% | 24.1% | ||
| Q4 24 | -17.1% | 25.5% | ||
| Q3 24 | -29.2% | 24.3% | ||
| Q2 24 | -18.9% | 21.6% | ||
| Q1 24 | -38.5% | 23.2% |
每股收益（稀释后）APLSTMP
| Q4 25 | $-0.40 | $6.72 | ||
| Q3 25 | $1.67 | $1.65 | ||
| Q2 25 | $-0.33 | $1.50 | ||
| Q1 25 | $-0.74 | $1.37 | ||
| Q4 24 | $-0.30 | $1.39 | ||
| Q3 24 | $-0.46 | $1.30 | ||
| Q2 24 | $-0.30 | $1.10 | ||
| Q1 24 | $-0.54 | $1.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $132.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $938.4M |
| 总资产 | $1.1B | $8.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSTMP
| Q4 25 | $466.2M | $132.8M | ||
| Q3 25 | $479.2M | $193.5M | ||
| Q2 25 | $370.0M | $212.6M | ||
| Q1 25 | $358.4M | $193.1M | ||
| Q4 24 | $411.3M | $134.4M | ||
| Q3 24 | $396.9M | $132.3M | ||
| Q2 24 | $360.1M | $70.9M | ||
| Q1 24 | $325.9M | $57.1M |
总债务APLSTMP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSTMP
| Q4 25 | $370.1M | $938.4M | ||
| Q3 25 | $401.2M | $788.8M | ||
| Q2 25 | $156.3M | $761.8M | ||
| Q1 25 | $164.2M | $741.4M | ||
| Q4 24 | $228.5M | $713.4M | ||
| Q3 24 | $237.1M | $719.9M | ||
| Q2 24 | $264.3M | $674.6M | ||
| Q1 24 | $266.7M | $667.9M |
总资产APLSTMP
| Q4 25 | $1.1B | $8.7B | ||
| Q3 25 | $1.1B | $8.5B | ||
| Q2 25 | $821.4M | $8.4B | ||
| Q1 25 | $807.3M | $8.2B | ||
| Q4 24 | $885.1M | $8.1B | ||
| Q3 24 | $901.9M | $8.0B | ||
| Q2 24 | $904.5M | $7.9B | ||
| Q1 24 | $831.9M | $7.8B |
负债/权益比APLSTMP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $38.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $31.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 16.4% |
| 资本支出强度资本支出/营收 | 0.1% | 3.6% |
| 现金转化率经营现金流/净利润 | — | 0.40× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $105.0M |
8季度趋势，按日历期对齐
经营现金流APLSTMP
| Q4 25 | $-14.2M | $38.9M | ||
| Q3 25 | $108.5M | $34.9M | ||
| Q2 25 | $4.4M | $18.9M | ||
| Q1 25 | $-53.4M | $22.2M | ||
| Q4 24 | $19.4M | $95.0M | ||
| Q3 24 | $34.1M | $21.2M | ||
| Q2 24 | $-8.3M | $27.3M | ||
| Q1 24 | $-133.0M | $23.2M |
自由现金流APLSTMP
| Q4 25 | $-14.3M | $31.9M | ||
| Q3 25 | $108.3M | $33.9M | ||
| Q2 25 | $4.4M | $18.3M | ||
| Q1 25 | $-53.4M | $20.9M | ||
| Q4 24 | $19.3M | $88.8M | ||
| Q3 24 | — | $18.9M | ||
| Q2 24 | $-8.4M | $26.3M | ||
| Q1 24 | $-133.3M | $21.9M |
自由现金流率APLSTMP
| Q4 25 | -7.1% | 16.4% | ||
| Q3 25 | 23.6% | 38.8% | ||
| Q2 25 | 2.5% | 22.1% | ||
| Q1 25 | -32.0% | 25.5% | ||
| Q4 24 | 9.1% | 115.1% | ||
| Q3 24 | — | 24.7% | ||
| Q2 24 | -4.2% | 36.2% | ||
| Q1 24 | -77.3% | 30.0% |
资本支出强度APLSTMP
| Q4 25 | 0.1% | 3.6% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.0% | 8.1% | ||
| Q3 24 | 0.0% | 2.9% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.2% | 1.9% |
现金转化率APLSTMP
| Q4 25 | — | 0.40× | ||
| Q3 25 | 0.50× | 1.47× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 4.82× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.74× | ||
| Q1 24 | — | 1.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TMP
暂无分部数据
